- with readers working within the Media & Information industries
- within Criminal Law, Accounting and Audit and Law Practice Management topic(s)
On August 21, 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical (“Lotus”) for AVT34, a proposed biosimilar to IMFINZI® (durvalumab), and AVT87, a proposed biosimilar to HEMLIBRA® (emicizumab).
In the United States, Alvotech and Lotus will have semi-exclusive commercialization rights, with Lotus commercializing through its subsidiary Alvogen. Alvotech will remain responsible for development, U.S. marketing authorizations, and product supply. Lotus will have exclusive commercialization rights in eight Asian markets and will handle local regulatory submissions.
The agreement could provide Alvotech with up to approximately $150 million in upfront and milestone payments, plus ongoing supply revenue.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]